Filed pursuant to Rule 433
Registration File No. 333-238958
Supplementing the Preliminary Prospectus Supplement dated June 16, 2020
(To Prospectus dated June 15, 2020)
Amerant Bancorp Inc.

Pricing Term Sheet
June 16, 2020

$46,000,000 5.75% Senior Notes due 2025

Issuer:
Amerant Bancorp Inc. (the “Company”)
 
Guarantor:
Amerant Florida Bancorp Inc.
 
Expected Ratings:*
BBB- by Kroll Bond Rating Agency
A- by Egan-Jones Ratings Company
 
Security Type:
Senior Unsecured Notes (the "Notes")
 
Securities:
5.75% Notes due 2025
 
Principal Amount:
$46,000,000
 
Maturity:
June 30, 2025
 
Coupon (Interest Rate):
5.75%
 
Price to Public:
100.00% of the principal amount
 
Use of Proceeds
We estimate that the net proceeds from the sale of the Notes, after deducting the underwriting discounts and certain offering expenses, will be approximately $45,310,000. We intend to use the net proceeds from this offering for general corporate purposes, which may include working capital, providing capital to support the organic growth of Amerant Bank, N.A., funding the opportunistic acquisition of similar or complementary financial service organizations and repaying outstanding indebtedness.
 
Conflicts of Interest:
Amerant Investments, Inc., Amerant Bank, N.A.’s securities broker-dealer subsidiary, will participate in the offering as a dealer with a concession from the public offering price of 50 basis points. Therefore, Amerant Investments is deemed to have a “conflict of interest” under FINRA Rule 5121 and, accordingly, the offering of the Notes will comply with the applicable requirements of FINRA Rule 5121.  The appointment of a “qualified independent underwriter” is not necessary in connection with this offering as the Notes are investment grade rated securities.
 
Yield to Maturity:
5.75%
 
Interest Payment Dates:
Semi-annually on June 30 and December 30 of each year, commencing on December 30, 2020
 
Record Date
The 15th calendar day immediately preceding the applicable Interest Payment Date
   
Par Call:
On or after March 30, 2025 (three months prior to the maturity date)
 
Trade Date:
June 16, 2020
 
Settlement Date:
June 23, 2020 (T + 5)
 
Denominations:
Minimum denominations of $1,000 and integral multiples of $1,000 in excess thereof
 
CUSIP / ISIN:
023576 AA9  / US023576AA95
 
Sole Book-Running Manager:
Raymond James & Associates, Inc.
 

*Note: A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time.

Under Rule 15c6-1 of the Securities Exchange Act of 1934, as amended, trades in the secondary market generally are required to settle in two business days, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade Notes on the date of pricing will be required, by virtue of the fact that the Notes initially will settle T+5, to specify an alternate settlement cycle at the time of any such trade to prevent a failed settlement. Purchasers of Notes who wish to trade the Notes on the date of pricing should consult their own advisors.

The issuer and guarantor have filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates.  Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer, the guarantor and this offering.  You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov.  Alternatively, the issuer, the underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling Raymond James & Associates, Inc. at 1-800-248-8863.

This pricing term sheet supplements the preliminary form of prospectus supplement filed by Amerant Bancorp Inc. and Amerant Florida Bancorp Inc. on June 16, 2020 (the “Preliminary Prospectus Supplement”) relating to its Prospectus, as amended, dated June 15, 2020. Terms used and not defined herein have the meanings given to them in the Preliminary Prospectus Supplement.